Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the KSA.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Allergic Rhinitis
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Allergic Rhinitis
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovasc®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Plavix®
  • Praluent®
    • Praluent®
    • Praluent®
    • Praluent 300 mg
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
LOGIN
REGISTER
SEARCH
Home | go to homepage
LOGIN
REGISTER
SEARCH
Home | go to homepage
SCIENCE
  • SCIENCE
  • Allergic Rhinitis
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Allergic Rhinitis
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovasc®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Plavix®
  • Praluent®
    • Praluent®
    • Praluent®
    • Praluent 300 mg
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
  • LOGIN
  • REGISTER
  • SEARCH
    • Home
    • Events

    Events

    Stay up to date and register for the latest events and view webinar recordings.

    Filters

    Therapeutical Areas
    Cardiovascular
    Diabetes
    Atopic Dermatitis
    Asthma
    Nasal Polyps
    Rare diseases
    Neurological-Disorders
    Anti Infectives
    Allergic Rhinitis
    Type of Content
    Watch
    Listen
    Read

    Action and Resistance Mechanisms of Antibiotics

    06:13

    VTE Safety Zone: Prof. Le Gal - The Role of Thromboprophylaxis for the Prevention of VTE

    VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis

    19:24

    Prof. Caprini - Assessing the VTE Risk in Hospital And Beyond

    Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management

    24:30

    Dyslipidemia Webinar

    06:58

    VTE Safety Zone: Prof. Juan Arcelus - Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery

    06:58

    VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery

    Venous Thromboembolism in Acutely Medically Ill Patients

    Hypertension - The Most Important Disease in Medicine II

    Hypertension - The Most Important Disease in Medicine

    Dyslipidemia Webisodes: Mortality data with Prof. Tunon

    1
    2
    3
    Home | go to homepage

    SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318,

    Fax: +966-12-663-6191

    For Medical Information, please contact: +966-12-669-3318, ksa.medicalinformation@sanofi.com

    To report any Product Technical Complaints, kindly contact: Email: quality.greatergulf@sanofi.com

    In case of any drug related adverse events, please contact:

    The National Pharmacovigilance Center (NPC):

    Call Center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa/

    And Sanofi Pharmacovigilance Department:

    Phone: +966-544-284-797, E-mail: Ksa_pharmacovigilance@sanofi.com

     

    MAT-SA-2100978/V4/NOV 2022

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.